134 related articles for article (PubMed ID: 16883014)
1. Anti-CD45 monoclonal antibody YAML568: A promising radioimmunoconjugate for targeted therapy of acute leukemia.
Glatting G; Müller M; Koop B; Hohl K; Friesen C; Neumaier B; Berrie E; Bird P; Hale G; Blumstein NM; Waldmann H; Bunjes D; Reske SN
J Nucl Med; 2006 Aug; 47(8):1335-41. PubMed ID: 16883014
[TBL] [Abstract][Full Text] [Related]
2. Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation.
Matthews DC; Appelbaum FR; Eary JF; Fisher DR; Durack LD; Bush SA; Hui TE; Martin PJ; Mitchell D; Press OW
Blood; 1995 Feb; 85(4):1122-31. PubMed ID: 7849300
[TBL] [Abstract][Full Text] [Related]
3. Optimal preloading in radioimmunotherapy with anti-cD45 antibody.
Kletting P; Kull T; Bunjes D; Luster M; Reske SN; Glatting G
Med Phys; 2011 May; 38(5):2572-8. PubMed ID: 21776793
[TBL] [Abstract][Full Text] [Related]
4. Biodistribution of yttrium-90-labeled anti-CD45 antibody in a nonhuman primate model.
Nemecek ER; Hamlin DK; Fisher DR; Krohn KA; Pagel JM; Appelbaum FR; Press OW; Matthews DC
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):787-94. PubMed ID: 15701869
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome.
Matthews DC; Appelbaum FR; Eary JF; Fisher DR; Durack LD; Hui TE; Martin PJ; Mitchell D; Press OW; Storb R; Bernstein ID
Blood; 1999 Aug; 94(4):1237-47. PubMed ID: 10438711
[TBL] [Abstract][Full Text] [Related]
6. Biokinetics of Radiolabeled Monoclonal Antibody BC8: Differences in Biodistribution and Dosimetry Among Hematologic Malignancies.
Matesan M; Fisher DR; Wong R; Gopal AK; Green DJ; Sandmaier BM; Bensinger W; Pagel JM; Orozco J; Press OW; Cassaday RD; Hutchinson E; Wanner M; Pal S; Thostenson C; Rajendran JG
J Nucl Med; 2020 Sep; 61(9):1300-1306. PubMed ID: 32169919
[TBL] [Abstract][Full Text] [Related]
7. Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities.
Buchmann I; Bunjes D; Kotzerke J; Martin H; Glatting G; Seitz U; Rattat D; Buck A; Döhner H; Reske SN
Cancer Biother Radiopharm; 2002 Apr; 17(2):151-63. PubMed ID: 12030109
[TBL] [Abstract][Full Text] [Related]
8. Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients.
Cremonesi M; Ferrari M; Chinol M; Stabin MG; Grana C; Prisco G; Robertson C; Tosi G; Paganelli G
Eur J Nucl Med; 1999 Feb; 26(2):110-20. PubMed ID: 9933344
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma.
Wiseman GA; White CA; Stabin M; Dunn WL; Erwin W; Dahlbom M; Raubitschek A; Karvelis K; Schultheiss T; Witzig TE; Belanger R; Spies S; Silverman DH; Berlfein JR; Ding E; Grillo-López AJ
Eur J Nucl Med; 2000 Jul; 27(7):766-77. PubMed ID: 10952488
[TBL] [Abstract][Full Text] [Related]
10. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
11. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
12. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Wiseman GA; White CA; Sparks RB; Erwin WD; Podoloff DA; Lamonica D; Bartlett NL; Parker JA; Dunn WL; Spies SM; Belanger R; Witzig TE; Leigh BR
Crit Rev Oncol Hematol; 2001; 39(1-2):181-94. PubMed ID: 11418315
[TBL] [Abstract][Full Text] [Related]
13. Selective radiation of hematolymphoid tissue delivered by anti-CD45 antibody.
Matthews DC; Badger CC; Fisher DR; Hui TE; Nourigat C; Appelbaum FR; Martin PJ; Bernstein ID
Cancer Res; 1992 Mar; 52(5):1228-34. PubMed ID: 1531324
[TBL] [Abstract][Full Text] [Related]
14. Improving anti-CD45 antibody radioimmunotherapy using a physiologically based pharmacokinetic model.
Kletting P; Bunjes D; Reske SN; Glatting G
J Nucl Med; 2009 Feb; 50(2):296-302. PubMed ID: 19164217
[TBL] [Abstract][Full Text] [Related]
15. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
Postema EJ; Börjesson PK; Buijs WC; Roos JC; Marres HA; Boerman OC; de Bree R; Lang M; Munzert G; van Dongen GA; Oyen WJ
J Nucl Med; 2003 Oct; 44(10):1690-9. PubMed ID: 14530488
[TBL] [Abstract][Full Text] [Related]
16. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
[TBL] [Abstract][Full Text] [Related]
17. Preparation and evaluation of the rhenium-188-labelled anti-NCA antigen monoclonal antibody BW 250/183 for radioimmunotherapy of leukaemia.
Seitz U; Neumaier B; Glatting G; Kotzerke J; Bunjes D; Reske SN
Eur J Nucl Med; 1999 Oct; 26(10):1265-73. PubMed ID: 10541824
[TBL] [Abstract][Full Text] [Related]
18. Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging.
Stillebroer AB; Zegers CM; Boerman OC; Oosterwijk E; Mulders PF; O'Donoghue JA; Visser EP; Oyen WJ
J Nucl Med; 2012 Jan; 53(1):82-9. PubMed ID: 22159179
[TBL] [Abstract][Full Text] [Related]
19. High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes.
Rajendran JG; Fisher DR; Gopal AK; Durack LD; Press OW; Eary JF
J Nucl Med; 2004 Jun; 45(6):1059-64. PubMed ID: 15181141
[TBL] [Abstract][Full Text] [Related]
20. α-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After 211At-Radioimmunotherapy for Hematopoietic Cell Transplantation.
Frost SH; Miller BW; Bäck TA; Santos EB; Hamlin DK; Knoblaugh SE; Frayo SL; Kenoyer AL; Storb R; Press OW; Wilbur DS; Pagel JM; Sandmaier BM
J Nucl Med; 2015 Nov; 56(11):1766-73. PubMed ID: 26338894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]